PTK2 and prostate cancer: In prostate cancer cells lacking β3, the reintroduction of a β3 mutant encompassing a point mutation (D723R) disrupting a putative salt bridge in the α‐ and the β‐cytoplasmic domains locked αvβ3 in an activated state capable of triggering constitutive FAK activation [48].